EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes

Reuters

Fri, Mar 22, 2024, 6:57 AM

In this article:

March 22 (Reuters) - The European Union's medicines regulator on Friday did not mention Eisai and Biogen's Alzheimer's drug in notes and recommendations following a meeting of a committee that reviews the use of drugs in the region.

The European Medicines Agency had said it would review the drug, lecanemab, this week.

(Reporting by Manas Mishra and Puyaan Singh in Bengaluru; Editing by Alan Barona, Josephine Mason and Shinjini Ganguli)

Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Motley Fool•16h ago
The CEO of packaged-food giant Kraft Heinz is obsessed with healthy eating and exercise—but also snacks on Lunchables several times a week
Kraft Heinz CEO Carlos Abrams-Rivera eats just two meals a day, between 11 a.m. and 7 p.m., as part of his intermittent-fasting routine.
Fortune•12h ago
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Benzinga•1d ago
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
Pharmaceutical Technology•2d ago
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Motley Fool•18h ago
Should You Buy Moderna Before May 12?
This ambitious biotech aims to launch 15 products over the coming five years.
Motley Fool•2d ago
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Zacks•2d ago
The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.
Business Insider•1d ago
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.
Barrons.com•2d ago
Pfizer hemophilia gene therapy arrives in US to uncertain future
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
BioPharma Dive•2d ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes

Recommended Stories

Forget Nvidia, These Unstoppable Stocks Are Better Buys

The CEO of packaged-food giant Kraft Heinz is obsessed with healthy eating and exercise—but also snacks on Lunchables several times a week

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

Should You Buy Moderna Before May 12?

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says

Pfizer Receives FDA Approval for Bleeding Disorder Treatment

Pfizer hemophilia gene therapy arrives in US to uncertain future